Neogen saw no growth in patent filings in April and highest growth of 2.99% in grants in May in Q2 2024. Compared to Q1 2024, Q2 2024 saw no growth in patent filings and grants by 0.99%. GlobalData’s DataBook provides a comprehensive analysis of Neogen‘s patent filings and grants. Buy the databook here.
Neogen has been focused on protecting inventions in United States(US) with five publications in Q2 2024
The United States(US) Patent Office dominates the patent filings and grants with nearly 60% filings and 50% grants. The United States(US), World Intellectual Property Organization(WIPO), European Patent Office(EPO), and Spain(ES) patent Office are among the top ten patent offices where Neogen is filings its patents. Among the top granted patent authorities, Neogen has 50% of its grants in United States(US), 25% in European Patent Office(EPO) and 25% in Spain(ES).
Roche could be the strongest competitor for Neogen
Patents related to industrial automation and robotics lead Neogen's portfolio
Neogen has the highest number of patents in industrial automation followed by, robotics. For industrial automation, nearly 50% of patents were filed and no patents were granted in Q2 2024.
First aid and wound care related patents lead Neogen portfolio followed by acute nasopharyngitis
Neogen has highest number of patents in first aid and wound care followed by acute nasopharyngitis.
For comprehensive analysis of Neogen's filings and grants, buy the databook here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.